| Literature DB >> 30682086 |
Magdalena Paczkowska1, Daria Szymanowska-Powałowska2, Mikołaj Mizera1, Dominika Siąkowska1, Wioletta Błaszczak3, Hanna Piotrowska-Kempisty4, Judyta Cielecka-Piontek1.
Abstract
A novel approach for drug design based on the oral carbapenem analog tebipenem pivoxil (TP) has been proposed. The formation of the tebipenem pivoxil-β-cyclodextrin (TP-β-CD) complex resulted in changes concerning physicochemical properties of TP, which is significant for planning the development of an innovative pharmaceutical formulation as well as in the modifications of biological activity profile of the studied delivery system. The inclusion of TP into β-cyclodextrin (β-CD) was confirmed by spectral (infrared and Raman spectroscopies) and thermal method (differential scanning calorimetry). Precise indications of TP domains responsible for interaction with β-CD were possible through a theoretical approach. The most important physicochemical modifications obtained as an effect of TP inclusion were changes in solubility and its rate depending on acceptor fluids, and an increase in chemical stability in the solid state. Biologically essential effects of TP and β-CD interactions were decreased TP permeability through Caco-2 cell monolayers with the use of efflux effect inhibition and increased antibacterial activity. The proposed approach is an opportunity for development of the treatment in resistant bacterial infections, in which along with physicochemical modifications induced by a drug carrier impact, a carrier synergy with a pharmacological potential of an active pharmaceutical substance could be used.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30682086 PMCID: PMC6347292 DOI: 10.1371/journal.pone.0210694
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1FT-IR absorption spectra for TP (1), β-CD (2), TP-β-CD inclusion complex (3) and calculated IR absorption TP spectrum (B3LYP/6-31G) (4).
Fig 2Raman spectra for TP (1), β-CD (2) and TP-β-CD inclusion complex (3).
Fig 3DSC thermograms of TP (1), β-CD (2) and TP-β-CD inclusion complex (3).
Fig 4The conformation of the most stable complex of TP and β-CD.
Relative energies of TP-β-CD complexes in respect to the angle of rotation of guest molecule rotated in the cavity.
| Relative rotation [°] | 0 | 30 | 60 | 90 | 120 | 150 | 180 |
| Conformer/energy [A.U.] | 0 | +0.051 | +0.029 | +0.046 | +0.029 | +0.029 | +0.029 |
Fig 5The chromatogram of TP in the presence its of the main impurity—tebipenem.
Validation parameters for HPLC-DAD method.
| Stability studies | Dissolution studies | Permeability studies | |||
|---|---|---|---|---|---|
| Parameter | water | gastric juice | phosphate buffer (pH 7.2) | donor | acceptor |
| Selectivity | |||||
| Peak symmetry factor (0.8–1.5 required) | 1.17 | 1.12 | 1.09 | 1.11 | 1.11 |
| The absence of interfering substances | confirmed | confirmed | confirmed | confirmed | confirmed |
| Limit of detection | 0.0446 | 0.0261 | 0.0085 | 0.0153 | 0.0153 |
| Limit of quantification | 0.1351 | 0.0789 | 0.0256 | 0.0464 | 0.0464 |
| Linearity y = ax + b | |||||
| a | 17.05 ± 0.28 | 30.88 ± 0.25 | 1.18 ± 0.01 | 61.19 ± 4.01 | 61.19 ± 4.01 |
| b | insignificant | insignificant | insignificant | insignificant | insignificant |
| Correlation coefficient (r) | 0.9998 | 0.9999 | 0.9998 | 0.9965 | 0.9965 |
| Range of linearity [mg mL-1] | 0.01–1.00 | 0.04–2.40 | 0.04–1.44 | 0.02–1.20 | 0.02–1.20 |
| Accuracy | |||||
| Recovery (95–105% required) [%] | 95.56 | 101.25 | 102.27 | 95.00 | 95.00 |
| Precision | |||||
| Concentration [mg mL-1] | 0.45 | 2.40 | 0.44 | 0.20 | 0.20 |
| Average of 6 injections [mg mL-1] | 0.43 | 2.43 | 0.45 | 0.19 | 0.19 |
| SD | 0.01 | 0.04 | 0.01 | 0.002 | 0.002 |
| RSD (<5% required) [%] | 2.32 | 1.65 | 2.22 | 1.05 | 1.05 |
Where SD is the average of standard deviations of determinations in the lower range of linearity and a is the directional coefficient of the plotted linear function; S standard deviation of slope; S standard deviation of intercept, t, calculated values of Student’s t-test, tα,f = 2.228 critical values of Student’s test for degrees of freedom f = 10 and significance level α = 0.05
Fig 6Phase-solubility diagram of TP inclusion complex in water.
Fig 7Dissolution profiles for TP (1), TP-β-CD physical mixture (2) and TP-β-CD inclusion complex (3) in artificial gastric juice at pH 1.2.
Fig 8Dissolution profiles for TP (1), TP-β-CD physical mixture (2) and TP-β-CD inclusion complex (3) in phosphate buffer at pH 7.2.
Kinetic and thermodynamic parameters of the degradation of TP in free form and in complex with β-CD.
| Temp. [K] | TP | TP-β-CD inclusion complex | to | ||
|---|---|---|---|---|---|
| (k ±Δk) [s-1] | Thermodynamic parameters | (k ±Δk) [s-1] | Thermodynamic parameters | ||
| RH ~ 76% | |||||
| 303 | (3.94 ± 0.52) × 10−6 | (3.69 ± 0.52) × 10−6 | 1.72 | ||
| RH = 0% | |||||
| 333 | (7.64 ± 0.02) × 10−6 | (6.80 ± 0.03) × 10−6 | 2.35 | ||
Δk = S tf E, activation energy; ΔH, enthalpy; ΔS, entropy; Ea = -aR; ΔH = E -TR; ΔS = R(ln A ln(kT)/h where: kB, Boltzmann’s constant (1.3807 10−23 JK-1); h, Planck’s constant (6.626 10-34Js); R, universal gas constant (8.314 K-1mol-1), T, temperature in K; a, vectorial coefficient of the Arrhenius; A, frequency coefficient a calculated for 298 K; t0, parameter of parallelism test, establishing significance of a coefficient of ln(ci) = f(t) plots.
Fig 9The semi-log plots of c = f(t) for degradation of TP and TP-β-CD inclusion complex studies at an increased relative air humidity (RH ~ 76%, T = 303–343 K) (A) and in dry air (RH = 0%, T = 333–363 K) (B).
The permeability values and efflux ratios of pure TP and TP-β-CD inclusion complex.
| Papp (A→B) | Papp (B→A) | Efflux ratio | |
|---|---|---|---|
| (mean ± SD) x 10−6 [cm s-1] | |||
| pure TP | 40.22 ± 0.51 | 75.14 ± 0.64 | 1.87 |
| TP-β-CD complex | 5.28 ± 0.01 | 8.96 ± 0.02 | 1.70 |
where Papp (A→B)—permeability value for A → B direction, Papp (B→A)—permeability value for B → A direction; A—donor, B—acceptor
Values of MIC (mg L-1) of TP and TP-β-CD inclusion complex against selected Gram-positive and Gram-negative bacteria.
| Microorganism | MIC (mg L-1) | ||
|---|---|---|---|
| pure TB | TP-β-CD | ||
| 1 | 125 | 125 | |
| 2 | 125 | 125 | |
| 3 | 125 | 125 | |
| 4 | 125 | 125 | |
| 5 | 31 | 15 | |
| 6 | 15 | 4 | |
| 7 | 125 | 125 | |
| 8 | 31 | 31 | |
| 9 | 250 | 125 | |
| 10 | 250 | 125 | |
| 11 | 125 | 62 | |
| 12 | 31 | 15 | |
| 13 | 250 | 250 | |
| 14 | 62 | 62 | |
| 15 | 125 | 125 | |
| 16 | 125 | 125 | |
| 17 | 250 | 125 | |
| 18 | 250 | 125 | |
| 19 | 125 | 125 | |
| 20 | 125 | 125 | |
*clinical isolates
⇩signs lower MIC values for TP-β-CD